COVID-19: Kumamoto University succeeds in creating corona antibody: effective for mutant strain
2021/07/14
Kumamoto University:
The research group has succeeded in creating an antibody for the new corona.
“Therapeutic drug that is effective against mutant strains” is likely to be born from Kumamoto.
Kumamoto University
Shuzo Matsushita Specially Appointed Professor
For those infected with the mutant strain, “the same effect of preventing aggravation and preventing infection as a vaccine” can be expected.
Neutralizing antibody created by Professor Matsushita of Kumamoto University.
Creation of new corona antibody:
The new corona antibody binds to the protrusions on the surface of the new coronavirus and prevents the virus from invading cells.
It replicates from the cells of a patient who has become severe and then rapidly recovered.
The effect was confirmed against both mutant strains such as British type and Indian type.
Specially Appointed Professor Matsushita:
“It works tremendously with a tremendous amount. It works amazingly.”
1/100 dose:
It is one-hundredth the dose of neutralizing antibody that is urgently approved and used for treatment in the United States.
It means that it can be expected to have the effect of preventing the aggravation of positive patients.
KAB Kumamoto Asahi Broadcasting »News
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19:
Highlights
• Neutralizing mAbs against SARS-CoV-2 are isolated from two convalescent patients
• Efficacy of antibodies is maintained against B.1.1.7 and mink cluster 5 variants
• B.1.351 from South Africa and P.1 from Brazil are resistant to mAbs and plasmas
• mAbs with high affinity for the RBD efficiently cross-neutralize B.1.351 and P.1
Summary
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs)
is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants,
we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG+) memory B cells.
Cell Reports